Floatz logo

Regorafenib

Gastrointestinal Stromal Tumor

Institut BergoniéSmall moleculePhase 4 / ApprovedDormant
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Gastrointestinal Stromal Tumor cohort.

Asset / SponsorPhaseRating
Midazolam
Blueprint Medicines Corporation
Phase 4BBB
Esomeprazole
Erasmus Medical Center
Phase 4BB
CAFFEINE
Markus Joerger
Phase 4BB
Imatinib
M.D. Anderson Cancer Center
Phase 2BB
Avapritinib
Blueprint Medicines Corporation
Phase 3BB

View all 49 →

Same molecule, other indications

Regorafenib is also rated in:

colorectal neoplasmActive
BB
Indicative · Phase 4
71 / 100
View asset →
colorectal adenocarcinomaActive
BB
Indicative · Phase 2
67 / 100
View asset →
colorectal cancerActive
BB
Indicative · Phase 4
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →